On Tuesday we’ll hop on BART to go down to the Hyatt Regency San Francisco for a portion of Fierce JPM Week. Our coverage ...

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in ...

A new study from the University of Iowa finds that many drug prices actually drop after pharmaceutical company mergers, ...

Eli Lilly partners with VC to launch 700 billion won biotech ecosystem fund Eli Lilly collaborates with a16z to create a vast ...

Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria B ...

Current treatments for dermatomyositis include various immunosuppressants and immunosuppressive agents, including ...

BFA Law Announces that a Class Action has been filed against BioAge Labs, Inc. - Contact the Firm if You Suffered Losses ...

NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ:BIOA) and certain of its ...

BioAge stated that it was collaborating with Eli Lilly and Company ("Lilly") in connection with STRIDES ... as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA ...

( MENAFN - GlobeNewsWire - Nasdaq) NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. ...

After years in development, the FDA has started its review of Pfizer and Eli Lilly’s new painkiller tanezumab ... Tanezumab and Regeneron/Teva’s fasinumab are the last survivors in a class ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...